Table 1. Baseline characteristics.
| Baseline Characteristics | Citicoline (n = 49) | Placebo (n = 50) | p-value |
|---|---|---|---|
| Age (median) in years +/- SD | 61 +/- 14.5 | 54.5 +/- 14.6 | 0.333 |
| Males (%) | 61.2 (30/49) | 60 (30/50) | 0.901 |
| Infarct (%) | 0.419 | ||
| • Right | 49 (24/49) | 36 (18/50) | |
| • Left | 51 (25/49) | 64 (32/50) | |
| Vascular territory (%) | 0.694 | ||
| • MCA | 81.6 (40/49) | 84 (42/50) | |
| • PCA | 12.2 (6/49) | 12 (6/50) | |
| • ACA | 0 | 2 (1/50) | |
| • ICA | 2.1 (1/49) | 2 (1/50) | |
| • Watershed | 4.1 (2/49) | 0 | |
| Median ASPECTS | 8 | 8 | 0.883 |
| Median BP (mm Hg) | |||
| • SBP | 150 | 148 | 0.309 |
| • DBP | 90 | 90 | 0.535 |
| Endovascular treatment (%) | 14.3 (7/49) | 16 (8/50) | 0.812 |
| Risk factors prevalence (%) | |||
| • Hypertension | 55.1 (27/49) | 62 (31/50) | 0.486 |
| • Diabetes mellitus | 26.5 (13/49) | 30 (15/50) | 0.702 |
| • Smoking | 32.6 (16/49) | 44 (22/50) | 0.246 |
| • Alcohol intake | 22.4 (11/49) | 22 (11/50) | 0.957 |
| • Dyslipidemia | 8.2 (4/49) | 10 (5/50) | 0.751 |
| • Heart disease | 26.5 (13/49) | 26 (13/50) | 0.670 |
| • Previous stroke | 28.6 (14/49) | 26 (13/50) | 0.323 |
| Median GCS at presentation | 15 | 15 | 0.527 |
| Time frames (Median) in minutes | |||
| • Onset to hospital | 135 | 162.5 | 0.139 |
| • Onset to thrombolysis/EVT | 165 | 200 | 0.244 |
| • Onset of drug treatment | 240 | 252.5 | 0.088 |
| Stroke subtypes- TOAST (%) | 0.546 | ||
| • Large vessel | 18.4 (9/49) | 6 (3/50) | |
| • Cardioembolic | 24.5 (12/49) | 22 (11/50) | |
| • Small vessel | 47.0 (23/49) | 52 (26/50) | |
| • Other classified | 0 | 0 | |
| • Unclassified | 10.1 (5/49) | 20 (10/50) | |
| Median hospital stay (days) | 6 | 6 | 0.931 |
| Baseline NIHSS (%) | 0.604 | ||
| • <8 | 24.5 (12/49) | 50 (25/50) | |
| • 8–14 | 51.0 (25/49) | 26 (13/50) | |
| • 15–22 | 20.4 (10/49) | 24 (11/50) | |
| • 23–42 | 4.1 (2/49) | 2 (1/50) | |
| Tenecteplase usage | 28.6 (14/49) | 26 (13/50) | 0.768 |